Narcolepsy Market Research Report - Forecast to 2027

Narcolepsy Market Research Report, By Type (Type 1, Type 2 Narcolepsy) Diagnosis (Poysomnogram, Multiple Sleep Latency Test) Treatment (Stimulants, Antidepressants, Sodium Oxybate) End Users (Hospitals, Retail Pharmacies) – Global Forecast Till 2027

ID: MRFR/Pharma/4246-HCR | February 2021 | Region: Global | 90 pages

Narcolepsy Market Scenario


Narcolepsy is a medical condition which is characterized by overwhelming daytime drowsiness and sudden attacks of sleep. Sometimes, this chronic sleep disorder can lead to a sudden loss of muscle tone (cataplexy), leading to weakness and loss of muscle control. Sleep paralysis, hallucinations, daytime sleepiness, fragmented sleep & insomnia, besides others are some of the most common symptoms of the disease. Increasing prevalence of narcolepsy and growing obese population are the major drivers of narcolepsy market growth during the forecast period. According to the Sleep Science journal in 2017, it was estimated that approximately 1 in every 2,000 people across the worldwide lives with narcolepsy. Moreover, from 2014-2015, the Australian Institute of Health and Welfare stated that approximately two-thirds, i.e., 63% of the Australian population which aged 18 years or more was estimated to be overweight or obese. Additionally, increasing demands for effective treatment of the disease followed by increasing research and development boost the narcolepsy market growth. However, lack of awareness and low per capita healthcare expenditure within the regional boundaries of middle and low-income countries is estimated to restrain the narcolepsy market during the forecast period.


Narcolepsy Market is expected to grow at an approximate CAGR of 8.2% during the forecast period.


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


 Figure 1:- Narcolepsy Market Share, by Region


 Narcolepsy Market


Sources: WHO, Sleep Science Journal, Australian Institute of Health and Welfare, National Institute of Neurological Disorders and Stroke, Annual Reports, Press Release, White Paper, And Company Presentation


segmentation


Narcolepsy Market is segmented on the basis of type, diagnosis, treatment, and end user.


 On the basis of the type, the narcolepsy market is segmented into type 1 narcolepsy, type 2 narcolepsy, and others.


On the basis of the diagnosis, the narcolepsy market is categorized into polysomnogram, multiple sleep latency test, others. On the basis of the treatment, the market is segmented into stimulants, antidepressants, sodium oxybate, and others. The stimulants segment is sub-segmented into modafinil, armodafinil, and others. The antidepressants segment is sub-segmented into tricyclics, selective serotonin and noradrenergic reuptake inhibitors, and others. The tricyclics segment is further segmented into imipramine, desipramine, clomipramine, and others. The selective serotonin and noradrenergic reuptake inhibitors segment are sub-segmented into venlafaxine, fluoxetine, and others. On the basis of the end users, the market is segmented into hospitals, clinics, retail pharmacies, and others.


Research Methodology


 Narcolepsy Market Research Methodology


Sources: WHO, Sleep Science Journal, Australian Institute of Health and Welfare, National Institute of Neurological Disorders and Stroke, Annual Reports, Press Release, White Paper, And Company Presentation


Regional Analysis


America dominates the narcolepsy market owing to a well-developed healthcare sector, high healthcare expenditure and a huge patient population. According to the National Institute of Neurological Disorders and Stroke in 2018, it is estimated that approximately 135,000 to 200,000 people in the United States are living with narcolepsy. Moreover, the presence of developed economies like U.S. and Canada and global players such as Mylan N.V., Ligand Pharmaceuticals, Inc., and others within the regional boundaries of the Americas fuels the narcolepsy market growth.


Europe is the second largest market for narcolepsy and is followed by Asia Pacific owing to the availability of funds for research, huge patient population, growing number of obese, and presence of developed economies like France, Italy, and Germany within the region. In 2016, according to the Eurostat, more than half of the adult population (51.6%) in European Union was considered to be over-weight.


Asia Pacific is estimated to be the fastest growing region for the narcolepsy market. Presence of developing economies like India and China within the region and developing healthcare sector facilitates the regional market growth. Moreover, favorable government policies boost the narcolepsy market growth.


The Middle East & Africa has the least share in the narcolepsy market.  Factors such as the presence of weak economies and stringent government policies especially within in the African region makes the market to lag within the region. Majority of the market in the Middle & Africa region is held by the Middle East. This can be attributed to a huge healthcare expenditure by the presence of the developed economies like Saudi Arabia, Kuwait, and Qatar within the region.


Key players in narcolepsy market


Jazz Pharmaceuticals plc (Republic of Ireland), BIOPROJET (Paris), Arena Pharmaceuticals, Inc. (U.S.), Graymark Healthcare, Inc. (U.S.), Mylan N.V.  (U.S., Teva Pharmaceutical Industries Ltd. (Israel), Novartis AG (Switzerland), Shire (Republic of Ireland), Shionogi Inc. (U.S.), Ligand Pharmaceuticals, Inc. (U.S.), and others



Frequently Asked Questions (FAQ) :


Narcolepsy is a medical condition wherein the patient suffers from chronic drowsiness during the day and sudden attacks of sleep.

Narcolepsy Market is expected to exhibit a strong 8.2% CAGR over the forecast period till 2023.

Growing awareness about narcolepsy is the major driver for the Narcolepsy Market.

The Americas dominate the global Narcolepsy Market, followed by Europe.

Leading players in the Narcolepsy Market include Arena Pharmaceuticals, BIOPROJET, and Jazz Pharmaceuticals, among others.

TABLE OF CONTENT


Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Narcolepsy Market, by Type

6.1 Introduction

6.2 Type 1 Narcolepsy

Market Estimates & Forecast, 2020 – 2027

6.3 Type 2 Narcolepsy

Market Estimates & Forecast, 2020 – 2027

6.4 Others

Chapter 7. Global Narcolepsy Market, by Diagnosis

7.1 Introduction

7.2 Polysomnogram

Market Estimates & Forecast, 2020 – 2027

7.3 Multiple Sleep Latency Test

Market Estimates & Forecast, 2020 – 2027

7.4 Others

Chapter 8. Global Narcolepsy Market, by Treatment

8.1 Introduction

8.2 Stimulants

Market Estimates & Forecast, 2020 – 2027

8.2.1 Modafinil

8.2.2 Armodafinil

8.2.3 Others

8.3 Antidepressants

Market Estimates & Forecast, 2020 – 2027

8.3.1 Tricyclics

Market Estimates & Forecast, 2020 – 2027

8.3.1.1 Imipramine

8.3.1.2 Desipramine

8.3.1.3 Clomipramine

8.3.1.4 Others

8.3.2 Selective Serotonin and Noradrenergic Reuptake Inhibitors

Market Estimates & Forecast, 2020 – 2027

8.3.2.1 Venlafaxine

8.3.2.2 Fluoxetine

8.3.2.3 Others

8.4 Sodium Oxybate

Market Estimates & Forecast, 2020 – 2027

8.5 Others

Chapter 9. Global Narcolepsy Market, by End User

9.1 Introduction

9.2 Hospitals

Market Estimates & Forecast, 2020 – 2027

9.3 Clinics

Market Estimates & Forecast, 2020 – 2027

9.4 Retail Pharmacies

Market Estimates & Forecast, 2020 – 2027

9.5 Others

Chapter 10. Global Narcolepsy Market, by Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Jazz Pharmaceuticals plc

12.1.1 Company Overview

12.1.2 Type Overview

12.1.3 Financials

12.2.4 Key Developments

12.1.5 SWOT Analysis

12.2 BIOPROJET

12.2.1 Company Overview

12.2.2 Type Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Arena Pharmaceuticals, Inc.

12.3.1 Company Overview

12.3.2 Type Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Graymark Healthcare, Inc.

12.4.1 Company Overview

12.4.2 Type/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Mylan N.V.

12.5.1 Company Overview

12.5.2 Type Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Teva Pharmaceutical Industries Ltd.

12.6.1 Company Overview

12.6.2 Type Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Novartis AG

12.7.1 Overview

12.7.2 Type Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Shire

12.8.1 Overview

12.8.2 Type Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Shionogi Inc.

12.9.1 Overview

12.9.2 Type Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 Ligand Pharmaceuticals, Inc.

12.10.1 Overview

12.10.2 Type Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Narcolepsy Market

Chapter 14 Appendix

LIST OF TABLES

Table 1 Narcolepsy Industry Synopsis, 2020 – 2027

Table 2 Global Narcolepsy Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Narcolepsy Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 5 Global Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 6 Global Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 7 Global Narcolepsy Market by End User, 2020 – 2027, (USD Million

Table 8 North America Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 9 North America Narcolepsy by Diagnosis, 2020 – 2027, (USD Million)

Table 10 North America Narcolepsy by Treatment, 2020 – 2027, (USD Million)

Table 11 North America Narcolepsy by End User, 2020 – 2027, (USD Million)

Table 12 U.S. Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 13 U.S. Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 14 U.S. Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 15 U.S. Narcolepsy Market by End User, 2020 – 2027, (USD Million)

Table 16 Canada Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 17 Canada Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 18 Canada Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 19 Canada Narcolepsy Market by End User, 2020 – 2027, (USD Million)

Table 20 South America Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 21 South America Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 22 South America Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 23 South America Narcolepsy Market by End User, 2020 – 2027, (USD Million)

Table 24 Europe Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 25 Europe Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 26 Europe Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 27 Europe Narcolepsy Market by End User, 2020 – 2027, (USD Million)

Table 28 Western Europe Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 29 Western Europe Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 30 Western Europe Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 31 Western Europe Narcolepsy Market by End User, 2020 – 2027, (USD Million)

Table 32 Eastern Europe Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 33 Eastern Europe Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 34 Eastern Europe Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 35 Eastern Europe Narcolepsy Market by End User, 2020 – 2027, (USD Million)

Table 36 Asia Pacific Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 37 Asia Pacific Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 38 Asia Pacific Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 39 Asia Pacific Narcolepsy Market by End User, 2020 – 2027, (USD Million)

Table 40 The Middle East & Africa Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 41 The Middle East & Africa Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 42 The Middle East & Africa Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 43 The Middle East & Africa Narcolepsy Market by End User, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Narcolepsy Market

Figure 3 Market Dynamics for Global Narcolepsy Market

Figure 4 Global Narcolepsy Market Share, by Type 2020

Figure 5 Global Narcolepsy Market Share, by Diagnosis 2020

Figure 6 Global Narcolepsy Market Share, by Treatment, 2020

Figure 7 Global Narcolepsy Market Share, by End User, 2020

Figure 8 Global Narcolepsy Market Share, by Region, 2020

Figure 9 North America Narcolepsy Market Share, by Country, 2020

Figure 10 Europe Narcolepsy Market Share, by Country, 2020

Figure 11 Asia Pacific Narcolepsy Market Share, by Country, 2020

Figure 12 The Middle East & Africa Narcolepsy Market Share, by Country, 2020

Figure 13 Global Narcolepsy Market: Company Share Analysis, 2020 (%)

Figure 14 Jazz Pharmaceuticals plc.: Key Financials

Figure 15 Jazz Pharmaceuticals plc.: Segmental Revenue

Figure 16 Jazz Pharmaceuticals plc.: Geographical Revenue

Figure 17 BIOPROJET: Key Financials

Figure 18 BIOPROJET: Segmental Revenue

Figure 19 BIOPROJET: Geographical Revenue

Figure 20 Arena Pharmaceuticals, Inc.: Key Financials

Figure 21 Arena Pharmaceuticals, Inc.: Segmental Revenue

Figure 22 Arena Pharmaceuticals, Inc.: Geographical Revenue

Figure 23 Graymark Healthcare, Inc.: Key Financials

Figure 24 Graymark Healthcare, Inc.: Segmental Revenue

Figure 25 Graymark Healthcare, Inc.: Geographical Revenue

Figure 26 Mylan N.V.: Key Financials

Figure 27 Mylan N.V. : Segmental Revenue

Figure 28 Mylan N.V. : Geographical Revenue

Figure 29 Teva Pharmaceutical Industries Ltd.: Key Financials

Figure 30 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 31 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 32 Novartis AG: Key Financials

Figure 33 Novartis AG: Segmental Revenue

Figure 34 Novartis AG: Geographical Revenue

Figure 35 Shire: Key Financials

Figure 36 Shire: Segmental Revenue

Figure 37 Shire: Geographical Revenue

Figure 38 Shionogi Inc.: Key Financials

Figure 39 Shionogi Inc.: Segmental Revenue

Figure 40 Shionogi Inc.: Geographical Revenue

Figure 41 Ligand Pharmaceuticals, Inc.: Key Financials

Figure 42 Ligand Pharmaceuticals, Inc.: Segmental Revenue

Figure 43 Ligand Pharmaceuticals, Inc.: Geographical Revenue